| Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease C Ma, MD Sacco, B Hurst, JA Townsend, Y Hu, T Szeto, X Zhang, ... Cell research 30 (8), 678-692, 2020 | 768 | 2020 |
| Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L MD Sacco, C Ma, P Lagarias, A Gao, JA Townsend, X Meng, P Dube, ... Science Advances 6 (50), eabe0751, 2020 | 350 | 2020 |
| Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors C Ma, Y Hu, JA Townsend, PI Lagarias, MT Marty, A Kolocouris, J Wang ACS pharmacology & translational science 3 (6), 1265-1277, 2020 | 230 | 2020 |
| The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor Y Hu, X Meng, F Zhang, Y Xiang, J Wang Emerging microbes & infections 10 (1), 317-330, 2021 | 166 | 2021 |
| Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir Y Hu, EM Lewandowski, H Tan, X Zhang, RT Morgan, X Zhang, ... ACS Central Science 9 (8), 1658-1669, 2023 | 163 | 2023 |
| Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay C Ma, MD Sacco, Z Xia, G Lambrinidis, JA Townsend, Y Hu, X Meng, ... ACS central science 7 (7), 1245-1260, 2021 | 134 | 2021 |
| Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors N Kitamura, MD Sacco, C Ma, Y Hu, JA Townsend, X Meng, F Zhang, ... Journal of medicinal chemistry 65 (4), 2848-2865, 2021 | 128 | 2021 |
| Discovery of di-and trihaloacetamides as covalent SARS-CoV-2 main protease inhibitors with high target specificity C Ma, Z Xia, MD Sacco, Y Hu, JA Townsend, X Meng, J Choza, H Tan, ... Journal of the American Chemical Society 143 (49), 20697-20709, 2021 | 106 | 2021 |
| The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition MD Sacco, Y Hu, MV Gongora, F Meilleur, MT Kemp, X Zhang, J Wang, ... Cell research 32 (5), 498-500, 2022 | 103 | 2022 |
| Progress and challenges in targeting the SARS-CoV-2 papain-like protease H Tan, Y Hu, P Jadhav, B Tan, J Wang Journal of medicinal chemistry 65 (11), 7561-7580, 2022 | 98 | 2022 |
| Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses Y Hu, C Ma, T Szeto, B Hurst, B Tarbet, J Wang ACS infectious diseases 7 (3), 586-597, 2021 | 82 | 2021 |
| Rational design of hybrid SARS-CoV-2 main protease inhibitors guided by the superimposed cocrystal structures with the peptidomimetic inhibitors GC-376, telaprevir, and boceprevir Z Xia, M Sacco, Y Hu, C Ma, X Meng, F Zhang, T Szeto, Y Xiang, Y Chen, ... ACS pharmacology & translational science 4 (4), 1408-1421, 2021 | 77 | 2021 |
| Expeditious lead optimization of isoxazole-containing influenza A virus M2-S31N inhibitors using the Suzuki–Miyaura cross-coupling reaction F Li, Y Hu, Y Wang, C Ma, J Wang Journal of medicinal chemistry 60 (4), 1580-1590, 2017 | 76 | 2017 |
| Influenza A virus nucleoprotein: a highly conserved multi-functional viral protein as a hot antiviral drug target Y Hu, H Sneyd, R Dekant, J Wang Current topics in medicinal chemistry 17 (20), 2271-2285, 2017 | 69 | 2017 |
| Enterovirus A71 antivirals: past, present, and future J Wang, Y Hu, M Zheng Acta Pharmaceutica Sinica B 12 (4), 1542-1566, 2022 | 56 | 2022 |
| Validating Enterovirus D68-2Apro as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68-2Apro Inhibitor R Musharrafieh, C Ma, J Zhang, Y Hu, JM Diesing, MT Marty, J Wang Journal of virology 93 (7), 10.1128/jvi. 02221-18, 2019 | 52 | 2019 |
| Enterovirus D68 antivirals: past, present, and future Y Hu, R Musharrafieh, M Zheng, J Wang ACS infectious diseases 6 (7), 1572-1586, 2020 | 51 | 2020 |
| SARS-CoV-2 main protease drug design, assay development, and drug resistance studies B Tan, R Joyce, H Tan, Y Hu, J Wang Accounts of chemical research 56 (2), 157-168, 2022 | 50 | 2022 |
| An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and-resistant influenza A viruses Y Hu, R Musharrafieh, C Ma, J Zhang, DF Smee, WF DeGrado, J Wang Antiviral research 140, 45-54, 2017 | 50 | 2017 |
| In vitro pharmacokinetic optimizations of AM2-S31N channel blockers led to the discovery of slow-binding inhibitors with potent antiviral activity against drug-resistant … Y Wang, Y Hu, S Xu, Y Zhang, R Musharrafieh, RK Hau, C Ma, J Wang Journal of medicinal chemistry 61 (3), 1074-1085, 2018 | 49 | 2018 |
